BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 7.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 427,152 shares of the company's stock after acquiring an additional 29,689 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.85% of Immunocore worth $13,297,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new position in Immunocore in the third quarter worth approximately $406,000. Crossmark Global Holdings Inc. purchased a new position in Immunocore in the third quarter worth approximately $866,000. Assetmark Inc. boosted its position in shares of Immunocore by 6.5% during the third quarter. Assetmark Inc. now owns 30,555 shares of the company's stock worth $951,000 after buying an additional 1,878 shares during the period. Principal Financial Group Inc. boosted its position in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after buying an additional 109,206 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after buying an additional 3,053 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Trading Up 0.5 %

Shares of NASDAQ IMCR traded up $0.16 during trading on Friday, hitting $32.28. 193,931 shares of the company traded hands, compared to its average volume of 232,528. Immunocore Holdings plc has a 1 year low of $29.72 and a 1 year high of $76.98. The company has a 50-day moving average price of $32.30 and a 200-day moving average price of $37.36. The firm has a market capitalization of $1.62 billion, a P/E ratio of -33.98 and a beta of 0.72. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million during the quarter, compared to analysts' expectations of $78.94 million. During the same period in the previous year, the company earned ($0.59) EPS. The business's quarterly revenue was up 23.7% compared to the same quarter last year. On average, equities analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and lowered their price target for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. UBS Group initiated coverage on Immunocore in a report on Thursday, October 24th. They set a "sell" rating and a $24.00 price objective on the stock. Needham & Company LLC lowered their price target on Immunocore from $78.00 to $71.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a report on Monday, September 9th. Finally, Barclays lowered their price objective on Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.